Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 10/20 | 0.40 |
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | RXRG | P48443 | 4/20 | 0.39 |
| ▸ | RXRB | P28702 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24410372 | 0.90 | RXRA (0.42) | RXRARXRGRXRBDGAT1ABCC4 | |
| SCHEMBL24410785 | 0.87 | SRC (0.40) | RIPK2SRCLMNAGAA | |
| SCHEMBL24410647 | 0.87 | RXRA (0.35) | RIPK2RXRARXRGRXRBDGAT1 | |
| SCHEMBL24411589 | 0.82 | RIPK2 (0.40) | RIPK2RXRARXRGRXRBSRC | |
| SCHEMBL24411612 | 0.82 | DGAT1 (0.40) | RIPK2RXRARXRGRXRBDGAT1 | |
| SCHEMBL24410401 | 0.81 | SRC (0.42) | RXRARXRGRXRBDGAT1SRC | |
| SCHEMBL8357891 | 0.81 | HPGD (0.51) | RIPK2SRCLMNA | |
| SCHEMBL24133460 | 0.81 | RIPK2 (0.39) | RIPK2SRCLMNAHTTLCK | |
| SCHEMBL24410875 | 0.81 | RIPK2 (0.61) | RIPK2DGAT1SRCLCKKDR | |
| SCHEMBL24410648 | 0.80 | RXRA (0.44) | RXRARXRGRXRBDGAT1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | RIPK2 332/4885RXRA 678/4885RXRG 527/4885 |
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | RIPK2 332/4885RXRA 678/4885RXRG 527/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | RIPK2 332/4885RXRA 678/4885RXRG 527/4885 |
| US-20220144816-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | RIPK2 332/4885RXRA 678/4885RXRG 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.